Connect with us

Technology

EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome

Published

on

This regulatory milestone marks an acceleration of the process around NT-I7’s potential first indication, after other recent positive news.NeoImmuneTech’s NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS.

ROCKVILLE, Md.  , June 4, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to NT-I7 (efineptakin alfa) for the treatment of Acute Radiation Syndrome (ARS).

This regulatory milestone follows the ODD granted to NT-I7 by the FDA in the US for the same indication in November 2023. It is the second ODD received by NT-I7 from the EMA, following the one granted in Idiopathic CD4+ Lymphocytopenia (ICL) in May 2017.

ARS is a critical condition resulting from a high dose of radiation exposure, causing severe, sometimes fatal damage to the bone marrow and the immune system. Currently, there are no treatments available that effectively promote T cell recovery after such exposure. NT-I7, a novel long-acting human interleukin-7 (IL-7), has shown promise to accelerate T cell reconstitution and enhance the immune response, offering a potential solution for this medical unmet need. Clinical studies have shown that NT-I7 significantly boosts T cell counts, while maintaining a high level of safety and tolerability.

NeoImmuneTech is actively developing NT-I7 in ARS through partnerships with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and Duke University. Recently, Duke University secured a $6 million grant from NIAID for NT-I7 development in ARS.

Luke Oh, Ph.D., President and Chief Executive Officer of NeoImmuneTech, said: “We are thrilled to see the deep interest of the scientific and regulatory community around the potential use of NT-I7 as a medical countermeasure in ARS. The EMA Orphan Drug Designation marks a new milestone for us, following our recent pre-IND discussions we had with the FDA to accelerate our development program. It is an important acknowledgment of the potential that NT-I7 holds in providing a beacon of hope for the treatment of ARS.”

ODD is a status assigned to a medicine intended for use against a rare disease or condition. The designation provides incentives to advance the development of treatments for rare diseases, including reduced fees for multiple steps in the development process, such as protocol assistance, marketing authorization applications, and inspections before authorization.

About Acute Radiation Syndrome (ARS)
Acute Radiation Syndrome (ARS) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (typically a matter of minutes or less). Examples of people who suffered from ARS are individuals exposed during the Hiroshima and Nagasaki atomic bombings, and the firefighters that responded after the Chernobyl Nuclear Power Plant incident in 1986.[1]

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements
The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

[1] https://www.cdc.gov/radiation-emergencies/hcp/clinical-guidance/ars.html?CDC_AAref_Val=https://www.cdc.gov/nceh/radiation/emergencies/arsphysicianfactsheet.htm

 

View original content:https://www.prnewswire.com/news-releases/ema-grants-orphan-drug-designation-to-neoimmunetechs-nt-i7-for-the-treatment-of-acute-radiation-syndrome-302163015.html

SOURCE The NeoImmuneTech, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

Published

on

By

Binance exceeded $5.6 billion in SPCXUSDT trading volume over last 24 hours, with over $9 billion in accumulated trading volume across SpaceX’s Pre-IPO and post-public listing

ABU DHABI, UAE, June 13, 2026 /PRNewswire/ — Binance has captured over 60% market share for SpaceX derivatives trading across centralized and decentralized exchanges, establishing itself as the leading liquidity venue for the product.

SpaceX perpetual futures (SPCXUSDT) are now Binance’s second–largest traded product, after Bitcoin perpetuals, reflecting strong global demand for exposure to major public–market events.

Binance also offers SpaceX stock and bStock tokenized securities, giving users greater portfolio diversification and hedging opportunities.

Key highlights

SpaceX perpetual futures became Binance’s No. 2 traded product, reflecting significant global demand for exposure to SpaceX’s public market debut.Binance captured >60% market share across CEX and DEX venues for SpaceX derivatives trading.Binance recorded over $5.6 billion in SPCXUSDT trading volume over the last 24 hours, as of June 13, 9:00 AM UTC (Coinglass, CoinMarketCap).Binance leads all CEX and DEX venues in SPCXUSDT Open Interest at $167.22 million (one-sided count).Binance recorded over $9 billion in accumulated SPCXUSDT trading volume across SpaceX’s Pre-IPO and post-public listing on Nasdaq.Binance successfully transitioned the Pre–IPO Perpetual into a standard TradFi Perpetual following SpaceX’s Nasdaq listing, with orderly price discovery anchored to publicly available valuation signals, share-count data, and market expectations.After SpaceX disclosed a higher share count in its S-1/A filing, Binance was the only exchange to successfully rebase its SpaceX Pre-IPO Perpetual contract to ensure users were not negatively impacted by dilution.

“SpaceX’s public listing was one of the most closely watched market events globally. SpaceX derivatives have become Binance’s second–largest traded product, capturing more than 60% market share across CEX and DEX venues, and demonstrating the appeal of our liquidity and product design,” said Shunyet Jan, Head of Spot and Derivatives Business at Binance.

“Our range of products — Pre–IPO futures, standard TradFi futures, stock trading, and tokenized securities — lets users access opportunities across different market lifecycles. This performance underlines our belief that better accessibility unlocks latent demand.”

Binance now offers over 7,000 stocks and ETFs for trading, alongside a broad range of digital assets, moving closer to its vision for a multi-asset financial super app that connects users to global market opportunities.

Disclaimer: Digital asset prices can be volatile. The value of your investment may go down or up and you may not get back the amount invested. You are solely responsible for your investment decisions and Binance is not liable for any losses you may incur. TradFi Perps are subject to high market risk and price volatility (particularly outside traditional market hours). In respect of Pre-IPO Perps which are subject to transition to TradFi Perp, there may be particular price volatility following official listing of the Underlying Asset and the share price may not ever reach the Final IPO Price. You may be called upon at short notice to make additional margin deposits or interest payments. If the required margin deposits or interest payments are not made within the prescribed time, your collateral may be liquidated. Moreover, you will remain liable for any resulting deficit in your account and interest charged on your account. All of your margin balance may be liquidated in the event of adverse price movement. Past performance is not a reliable predictor of future performance. TradFi Perps do not represent ownership of the relevant underlying asset. Before trading, you should make an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances, including the risks and potential benefits. Consult your own advisers, where appropriate. This information should not be construed as financial or investment advice. To learn more about how to protect yourself, visit our Responsible Trading page. For more information, see our Terms of Use, Exchange Rules, Clearing Rules, Exchange Procedures, Clearing Procedures, relevant Contract Specifications  and Risk Warning.

About Binance

Binance is a leading global blockchain ecosystem behind the world’s largest cryptocurrency exchange by trading volume and registered users. Binance is trusted by more than 320 million people in 100+ countries for its industry-leading security, transparency, trading engine speed, protections for investors, and unmatched portfolio of digital asset products and offerings from trading and finance to education, research, social good, payments, institutional services, and Web3 features. Binance is devoted to building an inclusive crypto ecosystem to increase the freedom of money and financial access for people around the world with crypto as the fundamental means. For more information, visit: https://www.binance.com.

SOURCE Binance

Continue Reading

Technology

LaVivid Hair Introduces Sports Hair Systems Collection for Men with Active Lifestyles

Published

on

By

LaVivid Hair launches a sports-focused hair systems collection designed for men who want breathable comfort, secure attachment, and natural-looking confidence during workouts, football season, summer activities, and everyday movement.

IRVINE, Calif., June 13, 2026 /PRNewswire-PRWeb/ — As global football excitement builds and more men return to sports, workouts, travel, and outdoor activities, LaVivid Hair has introduced its Sports Hair Systems Collection, a curated lineup of breathable, secure, and natural-looking hair systems designed for men with active lifestyles.

Men should not have to choose between looking natural and living actively. This collection was created for customers who want to work out, play sports, travel, and enjoy daily life with more confidence.

For many men experiencing hair loss, staying active can bring concerns that go beyond performance. They may wonder whether a hair system will stay secure during sweat, whether the hairline will remain natural during movement, or whether they can focus on a game, workout, or summer activity without checking their hair.

LaVivid Hair created the Sports Hair Systems Collection to help answer those concerns with practical product choices built around comfort, hold, realism, and easier maintenance.

The collection focuses on four active-wear priorities:

Breathable comfort: Lace and lace-center constructions help improve airflow during warm weather, workouts, and active days.

Secure attachment: Hybrid bases with skin or poly perimeters provide a stable bonding area for tape or glue, helping wearers feel more confident during movement.

Natural appearance: Lace fronts, graduated hairlines, and realistic density options help maintain a natural look from different angles.

Easy maintenance: Active lifestyles require simple bonding, cleaning, and regular upkeep, especially after sweat, heat, or long wear.

“Men should not have to choose between looking natural and living actively,” said a LaVivid Hair spokesperson. “This collection was created for customers who want to work out, play sports, travel, and enjoy daily life with more confidence.”

Top recommendations from the Sports Hair Systems Collection include Simois, Light Crius, Upgrade Ares, and Mars. Each system serves a different active-wear need, from breathable full lace comfort to hybrid lace-and-skin constructions that balance airflow with secure bonding.

Simois is designed for wearers who want a breathable lace center, a natural lace front hairline, and a skin perimeter for reliable attachment. Light Crius offers a lower-density look with French lace comfort and easy bonding, making it suitable for warm-weather wear and lighter active routines. Upgrade Ares combines a lace center with an ultra-thin skin front for wearers who want a natural front appearance with practical maintenance. Mars, a full lace option, is ideal for men who prioritize maximum breathability and lightweight comfort for light sports and summer activity.

For sports and active lifestyles, LaVivid Hair also recommends pairing the right base with dependable attachment products such as Ultra Hold Tape and Ultra Hold Glue. The right adhesive routine can help improve confidence during workouts, football matches, and daily movement.

The Sports Hair Systems Collection is now available at LaVivid Hair. Customers can explore the collection here:

https://www.lavividhair.com/collections/workout?utm_source=prweb&utm_medium=press-release&utm_campaign=prweb_260318&utm_id=prweb_260318&utm_content=sports_hair_systems_collection

To learn more about LaVivid men’s hair systems, visit:

https://www.lavividhair.com/?utm_source=prweb&utm_medium=press-release&utm_campaign=prweb_260318&utm_id=prweb_260318

About LaVivid Hair

LaVivid Hair provides hair replacement solutions for men around the world, offering natural-looking men’s hair systems designed for different lifestyles, preferences, and everyday needs. Through continuous product development and customer-focused innovation, LaVivid Hair helps wearers regain confidence with comfortable, realistic, and reliable hair systems.

Media Contact

Charlie Sue, LaVivid Hair, 1 833-879-0279, service@lavividhair.com, LaVivid Hair

View original content to download multimedia:https://www.prweb.com/releases/lavivid-hair-introduces-sports-hair-systems-collection-for-men-with-active-lifestyles-302797971.html

SOURCE LaVivid Hair

Continue Reading

Technology

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

Published

on

By

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ — Hexaware Technologies [NSE: HEXT], a global provider of IT solutions and services, today opened a new delivery center at Gujarat International Finance Tec-City (GIFT City), India’s premier international financial services hub. The center, inaugurated by Shri Bhupendra Patel, Hon’ble Chief Minister of Gujarat, will serve Hexaware’s global banking, financial services, and insurance (BFSI) clients across digital solutions, artificial intelligence (AI), cloud transformation, data engineering, and next-gen software services.

Hexaware’s established presence in Ahmedabad and Gujarat provides the foundation for this investment. With the GIFT City center, the company is building a technology and innovation hub that serves financial institutions across global markets. The company aims to create approximately 1,000 high-skilled jobs over the next three years, covering software engineering, digital transformation, AI, cloud, data analytics, business operations, and customer experience services.

“The establishment of Hexaware’s delivery center at GIFT City is a strong endorsement of Gujarat’s position as a globally competitive destination for financial services and technology. This is the kind of high-value investment the state has been building toward, and we are pleased to welcome Hexaware to this ecosystem,” said Chief Minister Bhupendra Patel.

“GIFT City represents a unique convergence of financial services, technology, and innovation. Our expansion into GIFT City aligns with our strategy of being closer to our customers while leveraging India’s exceptional talent ecosystem. We’re excited to contribute to the growth of Gujarat’s technology landscape and create meaningful career opportunities for skilled professionals,” said R. Srikrishna, CEO & Executive Director, Hexaware.

“GIFT City presents a compelling proposition for a company of Hexaware’s focus and scale. The financial services landscape, the quality of talent, and the policy framework the state government has put in place made this a clear decision for us,” said Vikash Kumar Jain, Chief Financial Officer, Hexaware.

The GIFT City center adds to Hexaware’s growing delivery footprint in India, supporting the company’s work with BFSI clients across global markets.

About Hexaware

Hexaware is a global technology and business process services company. Every day, Hexawarians wake up with a singular purpose: to create smiles through great people and technology. With offices across the world, we empower enterprises worldwide to realize digital transformation at scale and speed by partnering with them to build, transform, run, and optimize their technology and business processes. Learn more about Hexaware at https://hexaware.com.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/hexaware-expands-presence-in-gujarat-with-new-delivery-center-at-gift-city-302799597.html

Continue Reading

Trending